SCHEMBL19633006

SCHEMBL19633006

Nc1ccc2c(c1)CC[C@@H](N1CCCC1)CC2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1D P28221 2/20 0.44
GRIN2B Q13224 5/20 0.43
HRH3 Q9Y5N1 5/20 0.43
BRD4 O60885 1/20 0.42
ATAD2 Q6PL18 1/20 0.42
L3MBTL3 Q96JM7 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CYP2D6 P10635 2/20 0.40
KDM2B Q8NHM5 1/20 0.40
AXL P30530 2/20 0.39
AURKA O14965 1/20 0.39
EGFR P00533 1/20 0.39
RET P07949 1/20 0.39
MET P08581 1/20 0.39
KIT P10721 1/20 0.39
SRC P12931 1/20 0.39
PDGFRA P16234 1/20 0.39
KDR P35968 1/20 0.39
FLT3 P36888 1/20 0.39
TYRO3 Q06418 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL467492 1.00 HTR1D (0.44) HTR1DGRIN2BHRH3BRD4ATAD2
SCHEMBL24740684 0.92 HTR1D (0.47) HTR1DGRIN2BBRD4ATAD2L3MBTL3
SCHEMBL30300596 0.92 HTR1D (0.47) HTR1DGRIN2BBRD4ATAD2L3MBTL3
SCHEMBL24740615 0.90 HTR1D (0.48) HTR1DGRIN2BBRD4ATAD2L3MBTL3
SCHEMBL30612416 0.88 GRIN2B (0.45) HTR1DGRIN2BBRD4ATAD2
SCHEMBL29113501 0.88 GRIN2B (0.45) HTR1DGRIN2BBRD4ATAD2
SCHEMBL2060586 0.87 GRIN2B (0.44) HTR1DGRIN2BHRH3BRD4ATAD2
SCHEMBL4768314 0.86 HRH3 (0.56) HRH3CYP2D6
SCHEMBL1953271 0.86 HRH3 (0.49) GRIN2BHRH3BRD4ATAD2CYP2D6
SCHEMBL520119 0.85 HRH3 (0.44) GRIN2BHRH3BRD4ATAD2L3MBTL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024199102-A1 METHOD FOR PREPARING AXL INHIBITOR 南京正大天晴制药有限公司 2024-10-03 WO disclosed
WO-2024199100-A1 PREPARATION METHOD FOR AXL INHIBITOR INTERMEDIATE 南京正大天晴制药有限公司 2024-10-03 WO disclosed
US-20240246967-A1 AXL COMPOUNDS ARCUS BIOSCIENCES, INC. 2024-07-25 US disclosed
US-20240226115-A1 AXL INHIBITOR COMPOUNDS ARCUS BIOSCIENCES, INC. 2024-07-11 US disclosed
US-20240226115-A1 AXL INHIBITOR COMPOUNDS ARCUS BIOSCIENCES, INC. 2024-07-11 US disclosed
US-20240226115-A1 AXL INHIBITOR COMPOUNDS ARCUS BIOSCIENCES, INC. 2024-07-11 US disclosed
EP-4341261-A1 AXL COMPOUNDS Arcus Biosciences, Inc. (US) 2024-03-27 EP disclosed
CN-117337288-A AXL inhibitor compounds 艾库斯生物科学有限公司 2024-01-02 CN disclosed
CN-117295741-A AXL compounds 艾库斯生物科学有限公司 2023-12-26 CN disclosed
US-20230227484-A1 PYRIMIDINE COMPOUND AS AXL INHIBITOR NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) 2023-07-20 US disclosed
EP-4163278-A1 PYRIMIDINE COMPOUND AS AXL INHIBITOR Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (CN) 2023-04-12 EP disclosed
CN-115697993-A Pyrimidines as AXL inhibitors 南京正大天晴制药有限公司 2023-02-03 CN disclosed
CN-115557945-A Triazolopyridine compounds as AXL inhibitors 南京正大天晴制药有限公司 2023-01-03 CN disclosed
WO-2022246179-A1 AXL INHIBITOR COMPOUNDS ARCUS BIOSCIENCES, INC. (US) 2022-11-24 WO disclosed
WO-2022246177-A1 AXL COMPOUNDS ARCUS BIOSCIENCES, INC. (US) 2022-11-24 WO disclosed
WO-2021239133-A1 PYRIMIDINE COMPOUND AS AXL INHIBITOR 南京正大天晴制药有限公司 2021-12-02 WO disclosed
US-9994553-B2 Process for the purification of the Axl tyrosine receptor kinase inhibitor “R428” BERGENBIO AS (NO) 2018-06-12 US disclosed
US-9994553-B2 Process for the purification of the Axl tyrosine receptor kinase inhibitor “R428” BERGENBIO AS (NO) 2018-06-12 US disclosed
US-20170334884-A1 PROCESS FOR THE PURIFICATION OF THE AXL TYROSINE RECEPTOR KINASE INHIBITOR \"R428\ BERGENBIO ASA (NO) 2017-11-23 US disclosed
US-20170334884-A1 PROCESS FOR THE PURIFICATION OF THE AXL TYROSINE RECEPTOR KINASE INHIBITOR \"R428\ BERGENBIO ASA (NO) 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334884-A1 PROCESS FOR THE PURIFICATION OF THE AXL TYROSINE RECEPTOR KINASE INHIBITOR \"R428\ AXL, TYRO3, RET HTR1D 678/4885GRIN2B 1266/4885HRH3 573/4885
US-20230227484-A1 PYRIMIDINE COMPOUND AS AXL INHIBITOR AXL, FLT3, TYMP HTR1D 2800/4885GRIN2B 3068/4885HRH3 2517/4885
US-20240226115-A1 AXL INHIBITOR COMPOUNDS AXL, BTK, MERTK HTR1D 4076/4885GRIN2B 3423/4885HRH3 2491/4885
US-20240246967-A1 AXL COMPOUNDS AXL, FLT3, BTK HTR1D 4086/4885GRIN2B 3348/4885HRH3 2125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.